Ila Datar

Q: What is Ila Datar email address?

Email Ila Datar at datar_ila@lilly.com. This email is the most updated Ila Datar's email found in 2026.

Q: How to contact Ila Datar?

To contact Ila Datar send an email to datar_ila@lilly.com. (updated on February 14, 2025)

Advisor - Biology and Pharmacology at Eli Lilly and Company | Carmel, Indiana, United States

About Ila Datar

Ila Datar currently serves as an Advisor in Biology and Pharmacology at Eli Lilly and Company, where she leverages nearly a decade of expertise in oncology research to advance innovative therapeutic strategies. Her role focuses on early-phase discovery, particularly in the development of RNA therapeutics targeting extra-hepatic tissues, an area critical for expanding treatment options beyond traditional modalities. Ila’s deep understanding of molecular and cellular biology, combined with her proficiency in genetically engineered mouse models and advanced tissue analysis techniques, positions her as a key contributor to Lilly’s pipeline of targeted cancer therapies.

In her current position, Ila is instrumental in designing and executing preclinical studies that elucidate the complex immune responses involved in cancer progression and immune evasion. Her expertise in multiplex immunofluorescence, quantitative multispectral imaging, and RNA in situ hybridization allows her to characterize tumor microenvironments with high precision, informing the development of novel RNA-based interventions. Additionally, her skills in protein biochemistry and microtomy support the detailed analysis of tissue samples, enabling her to identify biomarkers and mechanisms of action that are essential for translational research.

Ila’s passion for understanding the dynamic interplay between cancer cells and immune responses drives her innovative approach to drug discovery. Her leadership in team management and mentoring fosters a collaborative environment that accelerates scientific discovery. With her comprehensive skill set and dedication, Ila Datar continues to contribute significantly to Lilly’s mission of developing transformative therapies for patients with cancer and other complex diseases.

Ila Datar Work